Investing
Evaline
Tsai, Ph.D.
As a Principal at Gigascale, Evaline brings sharp scientific rigor and founder empathy to her investing. An operator turned investor, she knows what it takes to commercialize breakthrough science and specializes in coaching first-time technical founders.
She serves as a Board Observer for Gigascale portfolio companies Arbor, Cocoon, Dioxycle, Panthalassa, Pasture Biosciences, Skouria, and Terradot. Evaline takes a rigorous approach to thesis development, mapping how novel science scales, what drives costs down, and where it can win in the market. She is currently participating in the Kauffman Fellows program and was named a Rising Star of Venture Capital by Business Insider in 2023.
Before Gigascale, Evaline spent two years at Fine Structure Ventures, where she was a board observer for Debut Biotech, Hoxton Farms, and Boston Metal, and invested in Commonwealth Fusion Systems and Phytoform. She also completed a fellowship at Costanoa Ventures.
Before Gigascale, Evaline spent two years at Fine Structure Ventures, where she was a board observer for Debut Biotech, Hoxton Farms, and Boston Metal, and invested in Commonwealth Fusion Systems and Phytoform. She also completed a fellowship at Costanoa Ventures.
Before becoming an investor, Evaline founded Cambridge Cancer Genomics, a Y Combinator–backed healthcare company, while completing her Ph.D. at the University of Cambridge in Chemical Engineering and Biotechnology. To gain operating experience at a growth-stage company, she joined Samsara as the first product manager for AI and machine learning, publishing three patents during her tenure.
Evaline also holds a B.S.E. in Chemical and Biological Engineering with Certificates in Sustainable Energy and Environmental Studies from Princeton.
